MedTrace Logo

Postoperative Enteral Immunonutrition in Gastric Cancer

NCT02647476 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2019-02-27

No results posted yet for this study

Summary

Immunomodulating enteral nutrition in the perioperative period may reduce postoperative complications in cancer patients. Little is known if this effect translates to the better survival.

The aim of study was to assess the impact of postoperative immunomodulating enteral nutrition on postoperative complications and survival of gastric cancer patients.

The group of 98 gastric cancer patients were randomly assigned for postoperative immunomodulating enteral nutrition n=44 (Reconvan ,Fresenius Kabi), or standard enteral nutrition n=54 (Peptisorb, Nutricia). Postoperative complications, mortality, 6-month, 1-year and 5-year survival were analyzed.

Conditions

Interventions

DIETARY_SUPPLEMENT

Immunomodulating nutrition (Reconvan)

protein rich, isocaloric, no-residue diet including arginine, glutamines and omega-3 fatty acids - Reconvan, Fresenius Kabi

DIETARY_SUPPLEMENT

Standard nutrition (Peptisorb)

oligopeptide, low-fat, isocaloric, non-residue diet

Sponsors & Collaborators

  • Jagiellonian University

    lead OTHER

Principal Investigators

  • Radosław Pach, MD PhD · 1st Dept. of General Surgery, Jagiellonian University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Primary Completion
2010-12-31
Completion
2015-10-31

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02647476 on ClinicalTrials.gov